SCHEMBL45122

SCHEMBL45122

O=C(CCSCc1cccc(C(=O)Nc2ccc(N3CCCCC3)cc2C(=O)NN=Cc2ccc(Cl)c(C(F)(F)F)c2)c1)Oc1c(F)c(F)c(F)c(F)c1F

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 12/20 0.45
SLC34A1 Q06495 1/20 0.45
SLC34A3 Q8N130 1/20 0.45
SLC20A1 Q8WUM9 1/20 0.45
RAB9A P51151 1/20 0.35
HPGD P15428 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
GAA P10253 1/20 0.35
CYP2D6 P10635 1/20 0.35
MAPT P10636 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.34
ADCYAP1R1 P41586 2/20 0.34
RAF1 P04049 1/20 0.34
ALDH1A1 P00352 1/20 0.33
ABCB1 P08183 1/20 0.33
ABCG2 Q9UNQ0 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL45121 1.00 SLC34A2 (0.45) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL266360 0.91 SLC34A2 (0.46) SLC34A2SLC34A1SLC34A3SLC20A1HPGD
SCHEMBL266361 0.91 SLC34A2 (0.46) SLC34A2SLC34A1SLC34A3SLC20A1HPGD
SCHEMBL41388 0.91 SLC34A2 (0.46) SLC34A2SLC34A1SLC34A3SLC20A1HPGD
SCHEMBL46618 0.90 SLC34A2 (0.42) SLC34A2SLC34A1SLC34A3SLC20A1HPGD
SCHEMBL274017 0.90 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1HPGD
SCHEMBL267363 0.90 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1HPGD
SCHEMBL267364 0.90 SLC34A2 (0.49) SLC34A2SLC34A1SLC34A3SLC20A1HPGD
SCHEMBL45028 0.89 SLC34A2 (0.43) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A
SCHEMBL45029 0.89 SLC34A2 (0.43) SLC34A2SLC34A1SLC34A3SLC20A1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2591354-B1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX INC (US) 2016-09-07 EP disclosed
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2014-01-23 US disclosed
EP-2591354-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT Ardelyx, Inc. (US) 2013-05-15 EP disclosed
WO-2012006475-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. (US) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC10A2, SLC34A2, SLC34A3 SLC34A2 2/4885SLC34A1 4/4885SLC34A3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.